5Kumar S K,Rajkumar S V, Dispenzieri A,et al. Im- proved survival in multiple myeloma and the impact ofnoveltherapies[J. Blood, 2008,111 (5) : 2516- 2 520.
6Chanan-Khan A A,Kaufman J L,Mehta J,et al. Ac- tivity and safety of bortezomib in multipie myeloma patients with advanced renal failure: a multicenter retrospective study[JJ. Blood,2007,109(6) : 2604- 2 606.
7Kenneth CA, Melissa A, William B, et al. NCCN clinical practice guidelines in oncology multiple myeloma version I [S]. 2011:17.
8Moreau P,Pylypenko H,Grosicki S,et al. Subcutaneous versus in- travenous administration of bortezomib in patients with relapsed multiple myeloma A randomised, phase 3, non - inferiority study[J]. Lancet Oncol,2011,12(5) :431 -440.
9Field- SmithA, Morgan GJ, Davies FE. Bortezomib in the treat- ment of multiple myeloma[J]. Ther Clin Risk Manag, 2006,2 (3) 271 -279.